Updated:
Invivyd
Dave Hering's Invivyd pivoted from Adagio Therapeutics' Covid-19 failure into a public biotech advancing variant-proof antibodies.
Invivyd
Invivyd emerged in 2020 as Adagio Therapeutics, a biopharmaceutical company founded to develop monoclonal antibodies against SARS-CoV-2. The firm's architecture shifted dramatically in 2022-2023 after its lead antibody, adintrevimab, failed to neutralize emerging Omicron variants, losing emergency-use authorization candidacy. CEO Dave Hering and Chairman Marc Elia restructured the company into Invivyd, retaining its Nasdaq listing and repurposing its antibody discovery platform toward variant-proof candidates. The firm's strategy centers on engineering antibodies designed to stay ahead of viral evolution. Invivyd's pipeline spans clinical-stage assets including pemivibart (formerly VYD222), a prophylactic monoclonal antibody for immunocompromised adults, and VYD2311, a next-generation candidate targeting broader pan-sarbecovirus neutralization. The company operates across North America and partners with contract development and manufacturing organizations for global supply chain access. Invivyd participates primarily in direct clinical development, occasionally engaging public-market investors and government agencies — it secured an initial $25 million Department of Defense contract for clinical trial support (per public filings, 2024). The firm's geographic focus remains concentrated on the United States, where it pursues FDA authorizations and emergency-use pathways for its antibody platforms. Invivyd maintains a lean biotech structure with a publicly traded platform and a leadership team drawn from Covid-19 antibody development veterans. In January 2024, Invivyd submitted an Emergency Use Authorization application to the FDA for pemivibart, seeking approval for pre-exposure prophylaxis in immunocompromised populations (per SEC filing, January 2024). The company has not disclosed adjacent philanthropic vehicles or family-office-style club structures, operating instead as a pure-play biopharmaceutical entity with R&D partnerships. Invivyd's structural differentiator lies in its post-failure recapitalization. Few biotech companies survive a lead-program failure, pivot, and retain their public listing while bringing a new clinical candidate to an FDA submission within one calendar year. This compressed turnaround — from adintrevimab's Omicron defeat to pemivibart's EUA filing — constitutes a rare governance stress-test in the antibody sector, where most firms dissolve or get acquired after a single pipeline collapse.
General information
Firm type
Asset Manager
Year founded
2020
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Waltham
Corporate office
Waltham, MA, United States
Principals
Dave Hering
Chief Executive Officer
Marc Elia
Chairman of the Board
Sector focus
Frequently asked questions
Who runs investment and clinical decisions at Invivyd?
Dave Hering serves as Chief Executive Officer, leading both corporate strategy and clinical development decisions. Marc Elia chairs the Board of Directors, providing governance oversight. The firm does not operate as a traditional investment vehicle — capital allocation decisions are driven by clinical trial milestones and FDA regulatory strategy rather than portfolio diversification or external LP commitments.
How did Invivyd emerge from Adagio Therapeutics?
Adagio Therapeutics was founded in 2020 to develop monoclonal antibodies for Covid-19. Its lead candidate, adintrevimab, lost efficacy against Omicron subvariants, and the company withdrew its Emergency Use Authorization application in 2022. Rather than dissolve, management restructured the entity into Invivyd, retained its Nasdaq listing (ticker IVVD), and advanced a next-generation antibody candidate, pemivibart, through clinical trials.
What is Invivyd's current pipeline composition?
Invivyd's clinical pipeline includes pemivibart (formerly VYD222), a monoclonal antibody for Covid-19 pre-exposure prophylaxis in immunocompromised adults, and VYD2311, a next-generation antibody engineered for broader neutralization against multiple sarbecoviruses. The firm uses proprietary engineering methods to target conserved epitopes that are less susceptible to viral mutation.
Does Invivyd accept outside investor capital or operate as a single-family office?
No. Invivyd is a publicly traded biopharmaceutical company listed on the Nasdaq under ticker IVVD. It raises capital through equity offerings and government contracts rather than through private fund commitments or family office allocations. It does not invest in external portfolio companies, funds, or real assets — all capital is directed toward internal antibody discovery, clinical trials, and manufacturing scale-up.
Has Invivyd received any government funding or partnerships?
Yes. Invivyd disclosed a contract with the U.S. Department of Defense in public filings to support clinical trial activities for pemivibart. The initial contract value was approximately $25 million. This government partnership supplements the firm's public-market equity financing and does not involve shared governance or joint venture structures.
What is Invivyd's known posture on co-investments or external collaborations?
Invivyd has not publicly disclosed participation in co-investment vehicles, syndicates, or for-profit partnerships with other pharmaceutical companies. The firm operates as an independent developer of antibody therapeutics, with occasional government contracts for clinical trial funding. No private-equity or venture-capital co-investor structures have been publicly reported.
Where is Invivyd's operational footprint concentrated?
Invivyd is headquartered in Waltham, Massachusetts, with all known R&D and administrative operations conducted within the United States. The firm has not disclosed international offices or subsidiary entities. Manufacturing and clinical trial activities involve contract partners rather than owned facilities, with global coordination managed from the Massachusetts base.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: